2026 Competition Pharma 
MedCity News
AUGUST 15, 2024
The first 10 drugs selected for Medicare price negotiations now have new prices set to take effect in 2026. Industry observers note that most of these drugs are older products facing generic competition soon, so greater industry impact will come as the program expands to more drugs in years to come.
pharmaphorum
JANUARY 10, 2023
Its ability to accelerate R&D programmes, energise real-time clinical decision making and sharpen connections between pharma organisations and clients is clear and they can combine to positively impact patient outcomes. Pharma is a highly regulated industry and that is often why it is slow to adopt new technologies,” says Kazuki.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
European Pharmaceutical Review
MARCH 13, 2023
“Not only does the location has offer competitive costs [but it has] proximity to our existing European-based production and commercial operations.” Full operations is provisionally planned for late 2026. The new plant will support the growing biosimilars sector. Work on the biologics plant in Slovenia is set to begin this year.
European Pharmaceutical Review
SEPTEMBER 14, 2023
Ultimately, this puts European businesses at a competitive disadvantage compared to other companies worldwide. Once adopted by the Council, the regulatory proposals are planned to come into force on 1 July 2028 (for BEFIT) and on 1 January 2026 (for the transfer pricing proposal).
Pharmaceutical Technology
MAY 11, 2023
The global pharma industry experienced a 9% drop in social media posts on internet of things in Q1 2023 compared with the previous quarter, with the highest share accounted for U.S. Of the 50 leading companies in the pharma industry, U.S. Buy the report here.
PM360
SEPTEMBER 21, 2023
Attention deficit hyperactivity disorder (ADHD) drug Vyvanse (lisdexamfetamine dimesylate) , manufactured by Takeda, also is facing generic competition. In the respiratory area with inhalers, it’s tough to get drugs approved, so the competition comes slowly,” he said. Starting in 2026, the provision will affect 10 Part D drugs.
PM360
APRIL 7, 2023
However, we expect drugs without strong therapeutic alternatives to have an advantage in negotiations, while drugs in highly competitive classes will be negotiating from a weaker position. pharma sales in 2020) and the size of 340B discounts (25-50%), companies may see significantly reduced revenues for important products.
Expert insights. Personalized for you.
325 
Let's personalize your content